Page 1 | Search Results | Blood | American Society of Hematology

1-12 of 12

Sort by

Sort Order Select

Journal Articles

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

Jia Ruan, John P. Leonard, Gui Zhen Chen, Zhengming Chen, John N. Allan, Sarah C. Rutherford, Brittany Hobbie, Katie Greig, Amelyn Rodriguez, Wayne Tam, David A. Bond, Bijal D. Shah, Kami J. Maddocks, Bhavneet Binder, Giorgio Inghirami, Olivier Elemento, Selina Chen-Kiang, Peter Martin

Blood (2022) 140 (Supplement 1): 175–177.

https://doi.org/10.1182/blood-2022-158656

Published: 2022

Journal Articles

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Blood (2020) 136 (Supplement 1): 7–8.

https://doi.org/10.1182/blood-2020-134699

Published: 2020

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Samuel Yamshon, MD, Peter Martin, FRCPC, MD MS, Bijal Shah, MD, Stephen J. Schuster, MD, Paul J Christos, Dr.P.H., M.S., Amelyn Rodriguez, BSN, RN, OCN, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Sarah C. Rutherford, MD, John N. Allan, MD, John P. Leonard, MD, Jia Ruan, MD PhD

Blood (2020) 136 (Supplement 1): 45–46.

https://doi.org/10.1182/blood-2020-138731

Published: 2020

Journal Articles

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Jia Ruan, Peter Martin, Paul Christos, Leandro Cerchietti, Wayne Tam, Bijal Shah, Stephen J. Schuster, Amelyn Rodriguez, David Hyman, Maria Nieves Calvo-Vidal, Sonali M. Smith, Jakub Svoboda, Richard R. Furman, Morton Coleman, John P. Leonard

Blood (2018) 132 (19): 2016–2025.

https://doi.org/10.1182/blood-2018-07-859769

Published: 2018

Journal Articles

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Jia Ruan, MD PhD, Peter Martin, FRCPC, MD MS, Paul J Christos, Dr.P.H., M.S., Leandro Cerchietti, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Wayne Tam, MD PhD, Amelyn Rodriguez, BSN, RN, OCN, David Hyman, Maria Nieves Calvo Vidal, PhD, Lidia Roman Gonzalez, Sonali M. Smith, MD, Jakub Svoboda, MD, Richard R. Furman, MD, Morton Coleman, MD, John P. Leonard, MD

Blood (2017) 130 (Supplement 1): 154.

https://doi.org/10.1182/blood.V130.Suppl_1.154.154

Published: 2017

Journal Articles

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Jia Ruan, MD PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R Furman, MD, Paul Christos, DrPH, Amelyn Rodriguez, RN, Louisa Drake, Jakub Svoboda, MD, Jessica Lewis, PA-C, Orel Katz, PA-C, Morton Coleman, MD, John P. Leonard, MD

Blood (2014) 124 (21): 625.

https://doi.org/10.1182/blood.V124.21.625.625

Published: 2014

Journal Articles

Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab

Jia Ruan, MD, PhD, Peter Martin, MD, Bijal D. Shah, MD, Stephen J. Schuster, MD, Sonali M. Smith, MD, Richard R. Furman, MD, Paul Christos, Amelyn Rodriguez, RN, Paige Wolstencroft, Jakub Svoboda, MD, Alison Bender, PA-C, Jessica Lewis, PA-C, Morton Coleman, MD, John P. Leonard, MD

Blood (2013) 122 (21): 247.

https://doi.org/10.1182/blood.V122.21.247.247

Published: 2013

Journal Articles

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Peter Martin, MD, Maurizio DiLiberto, PhD, Christopher E Mason, PhD, Scott A Ely, M.D., Jia Ruan, MD, PhD, Richard R. Furman, MD, David Chiron, PhD, Xiangao Huang, PhD, David C Madoff, M.D., Jonathan Navi, Jessica Lewis, PA-C, Alison Bender, PA-C, Amelyn Rodriguez, RN, June Greenberg, RN, Morton Coleman, MD, Selina Chen-Kiang, PhD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4393.

https://doi.org/10.1182/blood.V122.21.4393.4393

Published: 2013

Journal Articles

Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Tiffany Tang, MD, Peter Martin, MD, Rebecca L. Elstrom, MD, Jia Ruan, MD, PhD, Richard R. Furman, MD, Arcania Garcia, June Greenberg, RN, Amelyn Rodriguez, RN, Alison Bender, PA-C, Jessica Lewis, PA-C, Ari Melnick, MD, Leandro Cerchietti, MD, John P. Leonard, M.D.

Blood (2013) 122 (21): 4339.

https://doi.org/10.1182/blood.V122.21.4339.4339

Published: 2013

Journal Articles

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Rebecca L. Elstrom, MD, Leandro Cerchietti, MD, Peter Martin, MD, Richard R. Furman, MD, ShaoNing Yang, MS, Jia Ruan, MD, PhD, Paul Christos, Morton Coleman, MD, Amelyn Rodriguez, Madhu Mazumdar, Ari Melnick, MD, John P. Leonard, MD

Blood (2012) 120 (21): 3706.

https://doi.org/10.1182/blood.V120.21.3706.3706

Published: 2012

Journal Articles

Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis

John Mascarenhas, MD, Alice Mercado, RN, Amelyn Rodriguez, BSN, RN, OCN, Min Lu, PhD, Carla Kalvin, Xiaochun Li, PhD, Bruce Petersen, MD, Vesna Najfeld, PhD, Judith D. Goldberg, Sc.D., Ronald Hoffman, MD

Blood (2011) 118 (21): 794.

https://doi.org/10.1182/blood.V118.21.794.794

Published: 2011

Journal Articles

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

John Mascarenhas, MD, Xiaoli Wang, MD, PhD, Amelyn Rodriguez, BSN, RN, OCN, Mingjiang Xu, MD, PhD, Elaine Gorman, ANP-BC, Wenyong Zhang, MD, PhD, Judith D. Goldberg, Sc.D., Vesna Najfeld, Ph.D., Ronald Hoffman, MD

Blood (2009) 114 (22): 308.

https://doi.org/10.1182/blood.V114.22.308.308

Published: 2009

NARROW

Phase 2 Trial of Acalabrutinib-Lenalidomide-Rituximab (ALR) with Real-Time Monitoring of MRD in Patients with Treatment-Naïve Mantle Cell Lymphoma

A Phase I Study of Selinexor and R-ICE in Patients with Relapsed/Refractory Aggressive B-Cell Lymphomas

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma (MCL): 7-Year Analysis from a Multi-Center Phase II Study

Five-year follow-up of lenalidomide plus rituximab as initial treatment of mantle cell lymphoma

Initial Treatment with Lenalidomide Plus Rituximab for Mantle Cell Lymphoma: 5-Year Follow-up and Correlative Analysis from a Multi-Center Phase II Study

Sustained Remission with the Combination Biologic Doublet of Lenalidomide Plus Rituximab As Initial Treatment for Mantle Cell Lymphoma: A Multi-Center Phase II Study Report

Combination Biologic Therapy Without Chemotherapy As Initial Treatment For Mantle Cell Lymphoma: Multi-Center Phase II Study Of Lenalidomide Plus Rituximab

The Combination Of Palbociclib Plus Bortezomib Is Safe and Active In Patients With Previously Treated Mantle Cell Lymphoma: Final Results Of a Phase I Trial

Phase Ib Study Of Combination Epigenetic Therapy With 5-Azacitidine and Vorinostat In Patients With Relapsed Or Refractory DLBCL

Azacitidine Priming Prior to R-CHOP Is Feasible and Results in Global Demethylation, Restoration of TGF-Beta Pathway, and Improved Chemotherapy Sensitivity in Patients with Newly Diagnosed DLBCL

Prolonged Low Dose Therapy with a Pan-Deacetylase Inhibtor, Panobinostat (LBH589), in Patients with Myelofibrosis

A Phase I Study of LBH589, a Novel Histone Deacetylase Inhibitor in Patients with Primary Myelofibrosis (PMF) and Post-Polycythemia/Essential Thrombocythemia Myelofibrosis (Post-PV/ET MF).

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only